Hypercalciuria News and Research

RSS

Too much vitamin D may reduce bone density, say scientists

Excessive supplementation with vitamin D can cause bone loss and bone weakening, according to a new study.

6 Sep 2019

Too much Vitamin D could be harmful to bones

Vitamin D – an essential for healthy bones and calcium in the body, is prepared by the body when the skin is exposed to sunlight. A daily exposure of around 10 to 15 days is considered to be adequate for fulfilling the needs of vitamin D in the body.

4 Sep 2019

Excess lipoproteins, fatty acids may be linked to chronic kidney stones in children

A unique study recently published in the authoritative Pediatric Nephrology medical journal shows that excess lipoproteins and fatty acids may be associated with the development of painful and often chronic kidney stones in children.

17 Feb 2017

Study highlights role of intestinal calcium absorption in kidney stone formation

Measuring intestinal calcium absorption may help to identify individuals who are prone to develop kidney stones, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society of Nephrology.

10 Jun 2016

LEO Pharma's Enstilar gets FDA approval for topical treatment of plaque psoriasis

LEO Pharma Inc., a wholly owned U.S. subsidiary of LEO Pharma A/S, announced today that Enstilar has been approved by the U.S. Food and Drug Administration for the topical treatment of plaque psoriasis in adults 18 years of age and older.

19 Oct 2015

Shire announces availability of Natpara (parathyroid hormone) for injection in U.S.

Shire plc today announced that Natpara (parathyroid hormone) for injection is now available in the United States. The U.S. Food and Drug Administration approved Natpara as an adjunct to calcium and vitamin D to control hypocalcemia in patients with hypoparathyroidism on January 23, 2015.

1 Apr 2015

Calcium, vitamin D supplements may send blood levels too high for some women

Calcium and vitamin D are commonly recommended for older women, but the usual supplements may send calcium excretion and blood levels too high for some women, shows a new study published online today in Menopause, the journal of The North American Menopause Society.

18 Jun 2014

Recombinant hormone could REPLACE calcium supplements

Results from the phase III REPLACE trial of recombinant human parathyroid hormone (rhPTH) indicate the treatment can successfully combat the underlying deficit in hypoparathyroidism.

18 Oct 2013

NPS Pharmaceuticals president receives Ernst & Young Entrepreneur Award in Life Sciences category

NPS Pharmaceuticals, Inc. (NASDAQ: NPSP), a biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases worldwide, today announced that president and chief executive officer Francois Nader, M.D. has received the Ernst & Young Entrepreneur Of The Year® 2013 Award in the Life Sciences category in New Jersey. Dr. Nader was presented with the award at a special gala event on June 13 at the Hyatt Regency New Brunswick, New Jersey.

15 Jun 2013

EC grants European market authorization for Revestive to treat short bowel syndrome

Takeda Pharmaceutical Company Limited and NPS Pharmaceuticals, Inc., jointly announced today that the European Commission has granted European market authorization for the medicinal product teduglutide (trade name in Europe: Revestive) as a once-daily treatment for adult patients with short bowel syndrome.

5 Sep 2012

Researchers deciphered function of claudin-10 gene in the kidney

Sodium chloride, better known as salt, is vital for the organism, and the kidneys play a crucial role in the regulation of sodium balance. However, the underlying mechanisms of sodium balance are not yet completely understood.

24 Aug 2012

FDA committee to review NPS’ Gattex NDA in October

NPS Pharmaceuticals, Inc., a specialty pharmaceutical company developing therapeutics for rare gastrointestinal and endocrine disorders, today announced that the U.S. Food and Drug Administration (FDA) has notified the Company that its New Drug Application (NDA) for Gattex (teduglutide) will be discussed at the Gastrointestinal Drugs Advisory Committee meeting scheduled for October 16, 2012.

22 Aug 2012

FDA extends PDUFA action date for NPS Gattex NDA

NPS Pharmaceuticals, Inc., a specialty pharmaceutical company developing therapeutics for rare gastrointestinal and endocrine disorders, today announced that it has received a communication from the U.S. Food and Drug Administration extending the Prescription Drug User Fee Act action date for its New Drug Application for Gattex (teduglutide) by three months to December 30, 2012.

13 Aug 2012

Vitamin D and calcium supplements could increase risk of kidney stones

Calcium and vitamin D supplements are associated with high calcium levels in the blood and urine, which could increase the risk of kidney stones, a new study finds. The results will be presented Tuesday at The Endocrine Society's 94th Annual Meeting in Houston.

27 Jun 2012

European CHMP adopts positive opinion for teduglutide to treat short bowel syndrome

Takeda Pharmaceutical Company Limited and NPS Pharmaceuticals, Inc., jointly announced today that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product teduglutide (Revestive) as a once-daily treatment for adult patients with short bowel syndrome (SBS).

22 Jun 2012

Gattex may represent new treatment approach for short bowel syndrome

NPS Pharmaceuticals, Inc., a specialty pharmaceutical company developing innovative therapeutics for rare gastrointestinal and endocrine disorders, today reported the presentation of data at the Digestive Disease Week (DDW) meeting held May 19-22 in San Diego.

22 May 2012

NPS first quarter net loss increases to $10.6 million

NPS Pharmaceuticals, Inc., a specialty pharmaceutical company developing orphan therapeutics for rare gastrointestinal and endocrine disorders, today reported its results for the first quarter of 2012.

4 May 2012

Positive top-line results from NPSP558 Phase 3 study on hypoparathyroidism

NPS Pharmaceuticals, Inc., a specialty pharmaceutical company developing orphan therapeutics for rare gastrointestinal and endocrine disorders, today announced positive top-line results from REPLACE, a Phase 3 registration study of NPSP558, the company's bioengineered replica of human parathyroid hormone (rhPTH 1-84), in adult hypoparathyroidism patients.

7 Nov 2011

NPS announces new data from GATTEX Phase 3 study on short bowel syndrome

NPS Pharmaceuticals, Inc., a specialty pharmaceutical company developing innovative therapeutics for rare gastrointestinal and endocrine disorders, today announced new data from STEPS 2, a long-term open-label study, showing that GATTEX (teduglutide) was associated with achieving and maintaining clinically meaningful reductions in parenteral nutrition (PN) and intravenous (IV) fluid volume in adult subjects with short bowel syndrome.

1 Nov 2011

NPS announces data about hypoparathyroidism to be presented at ASBMR 2011 meeting

NPS Pharmaceuticals, Inc., a specialty pharmaceutical company developing innovative therapeutics for rare gastrointestinal and endocrine disorders, announced that data about hypoparathyroidism will be presented at the 2011 Annual Meeting of the American Society for Bone and Mineral Research (ASBMR) in San Diego, CA, September 16-20, 2011.

19 Sep 2011